Foghorn Therapeutics Inc (FHTX)
7.84
+0.12
(+1.55%)
USD |
NASDAQ |
Nov 22, 16:00
7.84
0.00 (0.00%)
After-Hours: 20:00
Foghorn Therapeutics Revenue (Quarterly): 7.808M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 7.808M |
| June 30, 2024 | 6.888M |
| March 31, 2024 | 5.05M |
| December 31, 2023 | 5.769M |
| September 30, 2023 | 17.48M |
| June 30, 2023 | 5.599M |
| March 31, 2023 | 5.309M |
| December 31, 2022 | 4.184M |
| September 30, 2022 | 6.634M |
| Date | Value |
|---|---|
| June 30, 2022 | 4.49M |
| March 31, 2022 | 3.92M |
| December 31, 2021 | 0.713M |
| September 30, 2021 | 0.041M |
| June 30, 2021 | 0.279M |
| March 31, 2021 | 0.286M |
| December 31, 2020 | 0.251M |
| September 30, 2020 | 0.179M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.041M
Minimum
Sep 2021
17.48M
Maximum
Sep 2023
4.405M
Average
4.49M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| Sana Biotechnology Inc | -- |
| Omega Therapeutics Inc | 2.612M |
| Moderna Inc | 1.855B |
| United Therapeutics Corp | 748.90M |
| CEL-SCI Corp | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -19.12M |
| Total Expenses (Quarterly) | 31.66M |
| EPS Diluted (Quarterly) | -0.31 |
| Enterprise Value | 168.45M |
| Profit Margin (Quarterly) | -244.9% |
| Earnings Yield | -24.49% |
| Normalized Earnings Yield | -23.90 |